Citation: | GU Jianjian. Expression of histone deacetylase 5 in gastric cancer and its relationship with tumor immune microenvironment[J]. Journal of Clinical Medicine in Practice, 2024, 28(12): 51-56. DOI: 10.7619/jcmp.20240921 |
To investigate the expression of histone deacetylase 5 (HDAC5) in gastric cancer and its relationship with tumor immune microenvironment.
Clinical materials of 120 patients with gastric cancer diagnosed and treated in the hospital from February 2021 to December 2023 were retrospectively analyzed. Immunohistochemical analysis was used to detect the expression level of HDAC5 in gastric cancer tissues, and the patients were divided into HDAC5 high-expression group and low-expression group. Univariate analysis, Logistic regression analysis, and receiver operating characteristic (ROC) curve were used to explore the related factors affecting HDAC5 expression. The levels of regulatory T cells (Treg), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), procalcitonin (PCT), hypersensitive C-reactive protein (hs-CRP), immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) in both groups were detected. Pearson correlation analysis was used to verify the correlation between HDAC5 expression level and tumor immune microenvironment in gastric cancer.
Univariate analysis showed that there were significant differences in tumor diameter, Borrmann classification and lymph node metastasis between the two groups (P < 0.05). Logistic regression analysis showed that tumor diameter, Borrmann classification and lymph node metastasis were independent risk factors affecting HDAC5 expression in gastric cancer (P < 0.05). ROC curve analysis showed that the values of area under the curve (AUC) for tumor diameter, Borrmann classification and lymph node metastasis were 0.608, 0.593 and 0.614, respectively. Pearson correlation analysis showed that HDAC5 expression level in gastric cancer patients was positively correlated with Treg content and inflammatory mediator indexes (P < 0.05), and negatively correlated with IgA, IgM and IgG (P < 0.05).
In patients with gastric cancer, the expression level of HDAC5 is related to tumor diameter, Borrmann classification and lymph node metastasis. High-level HDAC5 can directly affect the tumor immune microenvironment of gastric cancer.
[1] |
蒋祈, 张鹏, 陶凯雄. 美国国立综合癌症网络临床实践指南: 胃癌(2022. V2)更新解读[J]. 临床外科杂志, 2023, 31(1): 21-23. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWK202401028.htm
|
[2] |
杜晓辉, 晏阳, 刘帛岩. 2022版中国临床肿瘤学会胃癌诊疗指南更新解读[J]. 临床外科杂志, 2022, 30(9): 805-808. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWK202209002.htm
|
[3] |
高峰, 王美, 张懿薇, 等. 微小RNA-140-5p调控组蛋白去乙酰化酶4表达在胃癌转移中的作用及其机制[J]. 中华实验外科杂志, 2022, 39(9): 1684-1688.
|
[4] |
张文靖, 杨建萍, 李晟磊. 组蛋白去乙酰化酶6在胃癌组织中的表达及意义[J]. 广东医学, 2012, 33(2): 223-226. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX201202031.htm
|
[5] |
姜超, 许承, 陈霞, 等. MicroRNA-1254靶向组蛋白去乙酰化酶7调控胃癌细胞增殖和侵袭[J]. 肿瘤学杂志, 2021, 27(4): 255-259. https://www.cnki.com.cn/Article/CJFDTOTAL-XHON202104004.htm
|
[6] |
李显, 丁杰, 夏宇, 等. 组蛋白去乙酰化酶抑制剂及其衍生的多靶点抑制剂在胃肠道肿瘤中的研究进展[J]. 中国普通外科杂志, 2020, 29(10): 1251-1260. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202010016.htm
|
[7] |
吴海燕, 刘伟杰, 傅利强, 等. 基于内部预试验的样本量重估计在成组序贯设计中的应用研究[J]. 中国卫生统计, 2020, 37(6): 818-821, 827. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWT202006005.htm
|
[8] |
中华人民共和国国家卫生健康委员会医政医管局. 胃癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(9): 1137-1164.
|
[9] |
李林, 董振, 杨洁, 等. 去乙酰化转移酶SIRT7的作用及机制研究进展[J]. 生物工程学报, 2019, 35(1): 13-26. https://www.cnki.com.cn/Article/CJFDTOTAL-SHWU201901004.htm
|
[10] |
王双双, 高瑞梅, 于群德. 胃癌组织HDAC9蛋白高表达与病理特征及预后的关系[J]. 临床消化病杂志, 2023, 35(3): 207-212. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXH202303011.htm
|
[11] |
汤志明, 谷春明, 刘洋, 等. 曲古抑菌素A抑制胃癌细胞增殖的分子机制[J]. 医学研究生学报, 2020, 33(1): 7-11. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYB202001003.htm
|
[12] |
田峰, 徐建, 徐晓光. HDAC2与乙酰化P53k320在胃癌细胞中的表达及对其疗效的评价[J]. 山东医学高等专科学校学报, 2019, 41(6): 409-412, 396. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYB201906004.htm
|
[13] |
王志成. HDAC5和LSD1蛋白在胃癌组织中的表达及其预后的关系[D]. 长春: 吉林大学, 2022.
|
[14] |
杨婕, 魏婷, 许艳丽, 等. 两种新型的BTK和HDAC抑制剂在弥漫性大B细胞淋巴瘤细胞中的协同抗肿瘤作用[J]. 中国病理生理杂志, 2023, 39(10): 1814-1822. https://www.cnki.com.cn/Article/CJFDTOTAL-ZBLS202310010.htm
|
[15] |
霍寅萍, 褚庆霞. MiR-17-5p通过靶向HDAC4抑制PMEC细胞凋亡及促进EMT[J]. 临床肺科杂志, 2023, 28(8): 1173-1178. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFK202308009.htm
|
[16] |
刘亮亮, 马明, 常换换, 等. 喉癌中组蛋白去乙酰化酶1的表达及预后关系的研究[J]. 中国临床医生杂志, 2023, 51(9): 1025-1028. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS202309007.htm
|
[17] |
陈淑卿, 葛飞敏, 华育晖. 塞来昔布下调sirtuin 1表达抑制转化生长因子-β1诱导人胃癌细胞SGC-7901上皮细胞-间充质转化过程的研究[J]. 中国药师, 2019, 22(6): 1020-1025. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYSG201906009.htm
|
[18] |
李抄, 陈定宇, 张晓怡, 等. 基于TCGA数据库及转录组数据分析HDAC1基因在胃癌中的表达和临床意义[J]. 贵州医科大学学报, 2020, 45(2): 132-137, 150. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYB202002002.htm
|
[19] |
单怡茹, 田福华. 组蛋白乙酰化在消化系统肿瘤中的研究进展[J]. 中国医药科学, 2020, 10(24): 65-67. https://www.cnki.com.cn/Article/CJFDTOTAL-GYKX202024015.htm
|
[20] |
帅仁亚, 李晴宇, 范敏慧, 等. 大豆皂苷调控miR-584-5p/HDAC1通路对子宫内膜癌细胞增殖及凋亡的影响[J]. 中国现代医生, 2023, 61(33): 35-40. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS202333008.htm
|